A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis Academic Article uri icon

Overview

MeSH Major

  • Janus Kinase 1
  • Janus Kinase 2
  • Primary Myelofibrosis
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Splenomegaly

abstract

  • Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).

publication date

  • March 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4822164

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1110557

PubMed ID

  • 22375971

Additional Document Info

start page

  • 799

end page

  • 807

volume

  • 366

number

  • 9